[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626418":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":11,"centralContacts":26,"locations":32,"responsibleParty":45,"collaborators":11,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Seoul National University Bundang Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intra-lesional Boost Group","EXPERIMENTAL",null,[13,14],"Radiation: intra-lesional boost IMRT","Procedure: High Dose Rate Brachytherapy",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"RADIATION","intra-lesional boost IMRT","Patients receive Whole Pelvis (+\u002F- para-aortic field) radiotherapy 45-50.4 Gy in 25-28 fractions. An intra-lesional boost is delivered using SIB technique: 15 Gy in 3 fractions to the boost target (GTVp minus 0.7-1.0 cm margin).",[9],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"PROCEDURE","High Dose Rate Brachytherapy","Followed by CT or MRI-based HDR brachytherapy. Recommended dose is 27.5-30 Gy in 4-6 fractions to the HR-CTV using Iridium-192 source.",[9],[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"Keun-Yong Eom, MD, PhD","CONTACT","82-31-787-7653","978sarang@snubh.org",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":11,"cosmosGeoPoint":39,"geoPoint":44,"contacts":11},"RECRUITING","Seongnam-si","Gyeonggi-do","13620","South Korea",{"type":40,"coordinates":41},"Point",[42,43],127.13778,37.43861,{"lat":43,"lon":42},{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","KEUN YONG EOM","Clinical Assistant Professor","100626418","phase-2-intra-lesional-tumor-boost-for-bulky-cervical-cancer-100626418",false,"NCT07435376","Intra-lesional Tumor Boost for Bulky Cervical Cancer","A Prospective Phase 2 Clinical Trial of Intra-lesional Cervical Tumor Boost for Bulky Cervical Cancer","INTLECTUAL","Inclusion Criteria:\n\n* Patients with histologically confirmed squamous cell carcinoma of the cervix.\n* Patients with bulky primary tumor, defined as a tumor volume ≥ 60 cc OR a maximum diameter ≥ 6 cm.\n* Patients aged 19 to 80 years at the time of diagnosis.\n* Patients with an ECOG performance status of 0 to 2.\n* Patients who have voluntarily agreed to participate in the study.\n\nExclusion Criteria:\n\n* Diagnosis of other malignancies within 5 years prior to enrollment (Exceptions: carcinoma in situ of the breast and thyroid cancer).\n* Patients who are medically unfit for definitive concurrent chemoradiotherapy.\n* Patients who have received prior chemotherapy (neoadjuvant chemotherapy) before radiation therapy.\n* Patients with prior history of radiation therapy to the abdomen or pelvis.\n* Patients unable to provide informed consent due to mental or physical disabilities.","FEMALE","19 Years","80 Years",{"count":61,"type":62},17,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","The goal of this clinical trial is to learn if adding a radiation boost (intra-lesional boost) works to treat patients with large-sized cervical cancer. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\n* Does the extra radiation boost effectively reduce the tumor size before the internal radiation (brachytherapy) treatment begins?\n* What medical problems (side effects) do participants have when receiving this treatment?\n\nResearchers will give this intra-lesional boost to all participants during their standard radiation therapy to see if it helps shrink the tumor more than usual.\n\nParticipants will:\n\n* Receive radiation therapy to the pelvis with a targeted boost to the tumor for about 5 to 6 weeks\n* Visit the clinic daily for radiation treatment and regularly for checkups Have an MRI scan during the 4th or 5th week of treatment to measure the tumor size\n* Receive internal radiation therapy (brachytherapy) after finishing the external radiation\n* Visit the clinic for follow-up checkups and tests for up to 2 years",[68,69],"Cervical Cancer","Squamous Cell Carcinoma of Cervix",[71,72,73,74,75,76,77,78],"cervical cancer","bulky cervical cancer","squamous cell carcinoma","intra lesional boost","simultaneous integrated boost","imrt","radiotherapy","tumor volume reduction","2026-02-20",{"date":81,"type":82},"2026-02-27","ACTUAL",{"date":84,"type":82},"2025-02-23",{"date":86,"type":62},"2028-11-30",{"name":5,"class":6},1]